Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares

Stock News

03/10

Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1148853674"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148853674\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148853674?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148853674","market":"other","top_or_hot":-1,"title":"Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares","media":"Stock News","content":"<p>Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-10 10:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0196878994.USD","symbol_name":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","start_time":0,"source_url":"","article_id":"1148853674","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148853674","pubTimestamp":1773109105,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","02142":"和铂医药-B","06990":"科伦博泰生物-B","BK1583":"高瓴概念","BK1161":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard"},"translate_title":"TSLP双特异性抗体临床试验获批提振SKB BIO-B和HBM HOLDINGS-B股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"06990":1,"02142":1},"content_text":"Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}